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Abstract. Early diagnosis of dengue fever and COVID-19 is made very easy due to technological advancements. The non-structural
protein 1 antigen test strips are widely used in various regions; however, false-positive events have begun to be reported in the dengue-
endemic areas with the COVID-19 pandemic, even though statistically non-structural protein 1 antigens are very specific to dengue infection.
We reported a case of the false-positive non-structural protein 1 test in a patient with COVID-19 infection.
Keywords: Non-Structural Protein 1 (NS1) Antigen; Dengue; COVID-19; False-Positive.
Problem Statement and Analysis of the Recent Research
In December 2019, an outbreak of pneumonia caused by a
new type of coronavirus occurred in Wuhan, Hubei Province,
and has spread rapidly throughout the mainland China [1-3].
After the identification and isolation of the virus, the pathogen
causing pneumonia has initially been referred to as the 2019
novel coronavirus (2019-nCoV) [4], but later it was officially
renamed by the World Health Organization (WHO) as severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [5].
On January 30, 2020, WHO declared an outbreak of SARS-
CoV-2 as a Public Health Emergency of International Concern
that should be of particular concern. Compared to SARS-CoV,
which caused the SARS outbreak in 2003, SARS-CoV-2 has a
more substantial transmission capacity. The rapid increase in
confirmed cases made the prevention and control of COVID-
19 very serious [6].
Until July 9, 2020, SARS-COV-2 infection accounted for
11,841,326 cases worldwide with a total death of 544,736 people.
The areas with the highest SARS-CoV infection are the United
States with 6,125,802 cases, Europe with 2,827,789 cases, the
Eastern Mediterranean with 1,222,070 cases, Southeastern Asia
with 1,032,167 cases, and Africa with 397,942 cases [7]. As part
of the Southeast Asian country, Indonesia reported 70,736 cases
with a death toll of 3,417 cases on July 9, 2020 [8, 9].
Dengue fever is a systemically transmitted viral disease
that can go away on its own. Dengue fever can cause fever,
myalgia, rash, leukopenia, and thrombocytopenia [10, 11].
Clinical presentations and laboratory examination of dengue
fever can mimic other viral infections, including COVID-19
infection [12-14]. Such conditions have become a serious
problem. Indonesia is a region with a long history of dengue
fever [15].
Commercial tools for rapid in-vitro diagnosis of dengue
infection have been developed and adopted as strong evidence
for early laboratory confirmation of the disease in endemic
areas [16, 17]. The reported sensitivity of the non-structural
protein 1 (NS1) antigen test ranged between 48.5% and 58.6%,
and the specificity ranged between 92.5% and 99.4%. The
combined sensitivity of NS1 dengue antigen and the
immunoglobulin M (IgM) antibody test increased to 89.9-
92.9%, with a specificity of 75.0-88.8% [18].
In this case report, we discussed cross-reactivity of the
NS1 antigen test in confirmed cases of COVID-19 infection.
Case Presentation
A 24-year-old woman presented with fluctuating fever
reaching 39C. The patient was a medical officer at a hospital in
Central Java and had a history of contact with a patient
confirmed to be positive for COVID-19.
Fever tended to increase from noon, peaked in the afternoon
and lasted for four days. The patient complained of myalgia
and sore throat. Complaints of bumps, colds, and shortness of
breath were excluded. The patient’s blood pressure was 120/80
mmHg with a pulse rate of 80 beats per minute and oxygen
saturation of 99%. During auscultation of the heart, no murmurs
or irregularities were found; during lung auscultation, no
rhonchi and wheezes were found. Other physical examinations
were within normal limits. The patient was hospitalized and
treated with intravenous maintenance fluids: paracetamol - 3x1
gram, and ceftriaxone - 1x2 gram.
Laboratory tests on the 2nd day after symptom onset were
as follows: hemoglobin - 12.2 g/dL, hematocrit - 35.8%, platelets
- 210,000/L, erythrocytes - 4.14 million, leukocytes - 3160/L
with a lymphocyte count of 23.4%, basophils - 0.0%, neutrophils
- 60.8%, monocytes - 15.5%. The neutrophil-to-lymphocyte
ratio was 2.6, and the absolute lymphocyte count was 739 cells/
mm3. The posteroanterior (PA) chest X-ray taken on the 2nd
day after symptom onset and computed tomography (CT) scan
of the chest taken on the 4th day after symptom onset showed
a normal picture of the heart and lungs without any infiltrates
or increased vascularity (Fig. 3). On the 2nd day of fever, the
result of the NS1 test was positive.
Oropharyngeal and nasopharyngeal swab samples were
taken on the 4th day of symptom manifestation for polymerase
chain reaction (PCR) testing for the COVID-19 DNA strain.
Special treatment for COVID-19 was planned after obtaining
the PCR results.
Fever disappeared on the 4th day after symptom onset.
However, sore throat and myalgia persisted until the 7th day
after symptom onset. On the 7th day, the following symptoms
appeared: erythematous colored skin lesions of lenticular size
distributed symmetrically in the upper and lower limb regions,
multiple notably discrete maculopapular rashes, and itching
sensation (Fig.1, 2). The lesions did not appear in any region of
the body and were more pronounced on the 8th-9th days after
symptom onset. The patient was given oral loratadine - 3x10
mg and Nerilon cream for her skin lesions. The skin lesions
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disappeared by the 10th day after symptom onset.
On the 9th day after symptom onset, the PCR test results
were found to be positive for COVID-19. According to the
Recommendations of the Indonesian Medical Association for
mild symptoms, the patient was given the following treatment
regimen: azithromycin - 1x500 mg for three days, chloroquine
phosphate - 2x500 mg for five days, oseltamivir - 2x75 mg for
five days, 3x1 vitamin C tablets, and an asymptomatic drug in
the form of 1x30 mg lansoprazole to be taken with azithromycin.
Discussion
COVID-19 infection in areas where dengue virus is endemic
should be of particular concern. Gabriel Yan et al. reported 2
cases of COVID-19 patients coinfected with dengue fever in
Singapore. These cases shared similar clinical course of the
disease. They both cases tested negative for dengue using a
rapid test, then, they were discharged and returned to the
hospital for persistent fever and diagnosed with dengue fever
and SARS-CoV-2 coinfection [19]. Joob et al. also reported a
patient coinfected with SARS-CoV-2 and dengue virus in
Thailand. The patient first developed a petechial rash and was
diagnosed with dengue fever. However, the patient further
developed more respiratory symptoms and was re-diagnosed
with COVID-19 infection. These cases raised concern that
patients with fever can get infected with SARS-CoV-2 and
dengue simultaneously in dengue-endemic areas such as
Singapore, Thailand, and Malaysia in Southeast Asia and Brazil
in South America [20]. According to a recent study of 1,099
patients conducted by Guan et al., 87.9% of COVID-19 patients
had a fever, 67.7% of patients had cough, and 13.7% of patients
had headache. Some patients only experienced fever when
infected with SARS-CoV-2 [21]. In another study of 1,792
patients, 100% of patients had dengue fever, and 25.7% of
patients had headache [22].
COVID-19 patients can show the same clinical signs as
dengue patients. Furthermore, the cases in Singapore were
misdiagnosed and later confirmed with COVID-19 [19] that
indicated that misdiagnosis of patients with atypical symptoms
is possible. Therefore, steps should be taken to differentiate
patients with fever and headache from dengue fever and COVID-
19; these atypical symptoms should be of major concern,
especially in developing countries with a high incidence of
dengue fever, as in Southeast Asia and South America [23].
False-negative NS1 tests were reported in dengue serotypes
2 and 4 infections [24, 25]. NS1 tests were also reported to be
less sensitive in secondary dengue [16, 26, 27]. A little is known
about the cause of false-positive NS1 test, except for possible
-cross-reactivity with other flaviviruses and possibly with
cytomegalovirus (CMV) [28, 29].
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Fig. 1. Outline of symptoms experienced by patient
Fig. 2. Skin manifestations on the 4th day
 
Fig. 3. Patient’s thorax x-ray on the 2nd day
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patients with febrile illness evaluated with the NS1 test using
the SD Bioline Dengue Duo kit in Cambodia and the NS1
antigen enzyme-linked immunosorbent assay (ELISA; Platelia;
Bio-Rad Laboratories) in Vietnam [16, 30]. False-positive dengue
NS1 tests have not been reported in hematological
malignancies. Although there are case reports of dengue fever
causing hemophagocytosis [31, 32].
Conclusions
The rapid test and PCR test of nasopharyngeal swabs
carrying out in severe suspicion of COVID-19 help us a lot.
Furthermore, dengue NS1, IgM, and IgG tests should be used
to differentiate between these two infections with atypical
symptoms in countries where dengue virus is endemic.
Although the NS1 test is specific to dengue infection, we
reported a case of the false-positive NS1 test in a patient with
COVID-19 infection. We are very concerned that the rapid test,
the PCR test, the NS1 test, IgM, and the dengue IgG test were
performed on the patients with a high suspicion of being
infected with a second virus.
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